

Client: ARUP Example Report Only  
500 Chipeta Way  
Salt Lake City, UT 84108  
UNITED STATES

Physician: arup, arup

**Patient: Test, PAI-1 GENO 5G**

**DOB**

**Sex:** Male

**Patient Identifiers:** 46500

**Visit Number (FIN):** 46829

**Collection Date:** 3/3/2023 10:36

## Plasminogen Activator Inhibitor-1, PAI-1 (SERPINE1) Genotyping

ARUP test code 2004980

PAI-1 Specimen

Whole Blood

PAI-1 Interpretation

5G/5G

Indication for testing: Assess genetic risk for thrombosis.

Result: PAI-1 Genotype 5G/5G

Interpretation: Two copies of the PAI-1 5G allele (5G/5G) were detected. The 4G allele, which is associated with increased PAI-1 plasma activity levels, was not detected. This result does not exclude other genetic, or non-genetic, causes for thrombosis.

Recommendations: If clinically indicated, testing for other inherited or acquired thrombophilic disorders is recommended. For additional testing information, refer to the Antiphospholipid Syndrome, Hypercoagulable States, Thrombophilia, or Venous Thromboembolism topics at arupconsult.com.

This result has been reviewed and approved by [REDACTED]

Background Information: Plasminogen Activator Inhibitor-1, PAI-1 (SERPINE1) Genotyping:

Characteristics: The 4G allele within in the promoter region of the PAI-1 (SERPINE1) gene is associated with higher plasma PAI-1 activity when compared with the 5G allele. Heterozygosity or homozygosity for the 4G allele confers a risk for venous thromboembolism (VTE), especially in individuals with other thrombophilic risk factors, as well as a risk for myocardial infarction.

Frequency of the 4G Allele: Caucasian 0.52, Hispanic 0.38, African-American 0.13-0.28.

Variant Tested: The PAI-1 promoter 4G/5G polymorphism located in the promoter region of the SERPINE1 gene. NM\_000602.3(SERPINE1) c.-817dupG (from start of translation).

Inheritance: Autosomal dominant.

Clinical sensitivity: Unknown.

Methodology: Polymerase chain reaction and fluorescence monitoring.

Analytical Sensitivity and Specificity: 99 percent.

Limitations: Variants in the PAI-1 (SERPINE1) gene, other than the 4G/5G polymorphism, are not evaluated. Diagnostic errors can occur due to rare sequence variations.

This test was developed and its performance characteristics

H=High, L=Low, \*=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com  
500 Chipeta Way, Salt Lake City, UT 84108-1221  
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Test, PAI-1 GENO 5G  
ARUP Accession: 23-062-104017  
Patient Identifiers: 46500  
Visit Number (FIN): 46829  
Page 1 of 2 | Printed: 4/13/2023 9:14:49 AM

determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
PAI-1 Specimen	23-062-104017	3/3/2023 10:36:00 AM	3/3/2023 10:36:21 AM	4/6/2023 2:30:00 PM
PAI-1 Interpretation	23-062-104017	3/3/2023 10:36:00 AM	3/3/2023 10:36:21 AM	4/6/2023 2:30:00 PM

END OF CHART

H=High, L=Low, \*=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

**ARUP LABORATORIES | 800-522-2787 | aruplab.com**  
500 Chipeta Way, Salt Lake City, UT 84108-1221  
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Test, PAI-1 GENO 5G  
ARUP Accession: 23-062-104017  
Patient Identifiers: 46500  
Visit Number (FIN): 46829  
Page 2 of 2 | Printed: 4/13/2023 9:14:49 AM